CBP-HSF2 structural and functional interplay in Rubinstein-Taybi neurodevelopmental disorder.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
16 11 2022
Historique:
received: 14 05 2020
accepted: 24 10 2022
entrez: 17 11 2022
pubmed: 18 11 2022
medline: 22 11 2022
Statut: epublish

Résumé

Patients carrying autosomal dominant mutations in the histone/lysine acetyl transferases CBP or EP300 develop a neurodevelopmental disorder: Rubinstein-Taybi syndrome (RSTS). The biological pathways underlying these neurodevelopmental defects remain elusive. Here, we unravel the contribution of a stress-responsive pathway to RSTS. We characterize the structural and functional interaction between CBP/EP300 and heat-shock factor 2 (HSF2), a tuner of brain cortical development and major player in prenatal stress responses in the neocortex: CBP/EP300 acetylates HSF2, leading to the stabilization of the HSF2 protein. Consequently, RSTS patient-derived primary cells show decreased levels of HSF2 and HSF2-dependent alteration in their repertoire of molecular chaperones and stress response. Moreover, we unravel a CBP/EP300-HSF2-N-cadherin cascade that is also active in neurodevelopmental contexts, and show that its deregulation disturbs neuroepithelial integrity in 2D and 3D organoid models of cerebral development, generated from RSTS patient-derived iPSC cells, providing a molecular reading key for this complex pathology.

Identifiants

pubmed: 36385105
doi: 10.1038/s41467-022-34476-2
pii: 10.1038/s41467-022-34476-2
pmc: PMC9668993
doi:

Substances chimiques

CREB-Binding Protein EC 2.3.1.48
Heat-Shock Proteins 0
Histones 0
HSF2 protein, human 142297-91-4
Transcription Factors 0
EP300 protein, human EC 2.3.1.48
E1A-Associated p300 Protein EC 2.3.1.48

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7002

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s).

Références

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2048-2053
pubmed: 28174271
Physiol Rev. 2011 Apr;91(2):603-49
pubmed: 21527733
J Cell Biol. 2012 Aug 20;198(4):623-36
pubmed: 22908312
Neuron. 2012 Apr 26;74(2):314-30
pubmed: 22542185
Biochemistry. 2009 Mar 17;48(10):2115-24
pubmed: 19220000
Cell Rep. 2020 Jan 14;30(2):583-597.e6
pubmed: 31940498
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1681-6
pubmed: 21205885
Front Neurosci. 2017 May 19;11:248
pubmed: 28579939
PLoS One. 2021 Oct 15;16(10):e0258766
pubmed: 34653234
Nat Commun. 2013;4:2660
pubmed: 24154492
Hum Mol Genet. 2003 Feb 15;12(4):441-50
pubmed: 12566391
Mol Cell Biol. 1993 Mar;13(3):1392-407
pubmed: 8441385
Nat Rev Mol Cell Biol. 2018 Jan;19(1):4-19
pubmed: 28852220
Sci Adv. 2017 May 31;3(5):e1603014
pubmed: 28580422
Front Mol Neurosci. 2018 Apr 30;11:142
pubmed: 29760652
Mol Cell Biol. 2015 Apr;35(8):1390-400
pubmed: 25645927
Dev Cell. 2010 Jan 19;18(1):114-25
pubmed: 20152182
EMBO J. 2002 Jun 3;21(11):2591-601
pubmed: 12032072
Neurosci Lett. 2020 Apr 23;725:134895
pubmed: 32147500
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24310-24316
pubmed: 31685606
Semin Cell Dev Biol. 2017 Sep;69:172-182
pubmed: 28694114
Nat Protoc. 2014 Oct;9(10):2329-40
pubmed: 25188634
Mol Cell Biol. 2010 Dec;30(24):5608-20
pubmed: 20937767
Genes Dev. 2006 Apr 1;20(7):836-47
pubmed: 16600913
Mol Neurobiol. 2020 Sep;57(9):3685-3701
pubmed: 32562237
Genesis. 2003 May;36(1):48-61
pubmed: 12748967
Mol Cell Biol. 2015 Jul;35(14):2530-40
pubmed: 25963659
Nat Commun. 2017 Feb 13;8:14405
pubmed: 28194040
Stem Cell Res. 2018 Jul;30:130-140
pubmed: 29883886
Curr Protoc Cell Biol. 2012 Jun;Chapter 8:Unit8.8
pubmed: 23129118
Curr Cancer Drug Targets. 2011 Mar;11(3):239-53
pubmed: 21247388
Nat Struct Mol Biol. 2016 Feb;23(2):147-54
pubmed: 26727490
Cell. 2014 Feb 27;156(5):975-85
pubmed: 24581496
Clin Genet. 2015 Nov;88(5):431-40
pubmed: 25388907
FEBS Lett. 2013 Aug 19;587(16):2506-11
pubmed: 23831576
Hum Genet. 1993 Jul;91(6):538-46
pubmed: 8340107
J Pediatr Genet. 2015 Sep;4(3):177-86
pubmed: 27617129
Mol Cell. 2011 Oct 21;44(2):325-40
pubmed: 21906983
Nat Struct Mol Biol. 2013 Sep;20(9):1040-6
pubmed: 23934153
J Biol Chem. 2002 Nov 8;277(45):43168-74
pubmed: 12205094
Nat Rev Mol Cell Biol. 2010 Aug;11(8):545-55
pubmed: 20628411
Front Cell Neurosci. 2019 Jun 04;13:244
pubmed: 31213986
Dev Cell. 2010 Mar 16;18(3):472-9
pubmed: 20230753
Chem Biol. 2010 May 28;17(5):471-82
pubmed: 20534345
Cell Rep. 2017 Apr 4;19(1):50-59
pubmed: 28380362
EMBO Mol Med. 2014 Jul 15;6(8):1043-61
pubmed: 25027850
J Biol Chem. 2014 May 2;289(18):12705-15
pubmed: 24619424
Mol Cell Proteomics. 2011 Oct;10(10):M111.013284
pubmed: 21890473
Hum Mol Genet. 2008 Sep 15;17(18):2776-89
pubmed: 18558631
Science. 2003 Apr 11;300(5617):342-4
pubmed: 12690203
Mol Cell Biol. 2002 Apr;22(7):1961-70
pubmed: 11884585
Nat Struct Mol Biol. 2018 Jul;25(7):631-640
pubmed: 29967540
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3388-97
pubmed: 23959860
Cell Rep. 2017 Mar 14;18(11):2702-2714
pubmed: 28297673
Chem Rev. 2015 Mar 25;115(6):2419-52
pubmed: 25594381
Nucleic Acids Res. 2014 Feb;42(4):2112-25
pubmed: 24253305
Nat Rev Neurosci. 2015 Sep;16(9):551-63
pubmed: 26289574
J Biol Chem. 2007 Mar 9;282(10):7077-86
pubmed: 17213196
Cell Adh Migr. 2015;9(3):183-92
pubmed: 25869655
Clin Genet. 2019 Mar;95(3):420-426
pubmed: 30633342
Cell Stem Cell. 2018 Jan 4;22(1):128-137.e9
pubmed: 29276142
J Autism Dev Disord. 2017 Nov;47(11):3321-3332
pubmed: 28748333
Cell. 2021 Apr 15;184(8):2084-2102.e19
pubmed: 33765444
Neuron. 2014 May 7;82(3):560-72
pubmed: 24726381
Mol Biol Cell. 2009 Mar;20(5):1340-7
pubmed: 19129477
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2392-7
pubmed: 9122205
J Mol Biol. 2015 Dec 4;427(24):3793-816
pubmed: 26482101
Neuron. 2004 Oct 14;44(2):279-93
pubmed: 15473967
Cell. 1997 Dec 12;91(6):741-52
pubmed: 9413984
Genes Dev. 2018 Jun 1;32(11-12):763-780
pubmed: 29899142
Prog Mol Biol Transl Sci. 2014;128:139-76
pubmed: 25410544
J Mol Biol. 2004 Mar 26;337(3):521-34
pubmed: 15019774

Auteurs

Aurélie de Thonel (A)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France. aurelie.dethonel@univ-paris-diderot.fr.

Johanna K Ahlskog (JK)

Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Kevin Daupin (K)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.

Véronique Dubreuil (V)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.

Jérémy Berthelet (J)

Université de Paris, CNRS, Unité de Biologie Fonctionnelle et Adaptative, Paris, France.

Carole Chaput (C)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
Ksilink, Strasbourg, France.

Geoffrey Pires (G)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.

Camille Leonetti (C)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.

Ryma Abane (R)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.

Lluís Cordón Barris (LC)

Laboratory of Molecular Regulation of Neurogenesis, GIGA-Stem Cells and GIGA-Neurosciences, Interdisciplinary Cluster for Applied Genoproteomics (GIGA-R), University of Liège, CHU Sart Tilman, Liège, Belgium.

Isabelle Leray (I)

Université de Nantes, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000, Nantes, France.

Anna L Aalto (AL)

Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Sarah Naceri (S)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.

Marine Cordonnier (M)

INSERM, UMR1231, Laboratoire d'Excellence LipSTIC, Dijon, France.
University of Bourgogne Franche-Comté, Dijon, France.
Département d'Oncologie médicale, Centre Georges-François Leclerc, Dijon, France.

Carène Benasolo (C)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.

Matthieu Sanial (M)

CNRS, UMR 7592 Institut Jacques Monod, F-75205, Paris, France.

Agathe Duchateau (A)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.

Anniina Vihervaara (A)

Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
KTH Royal Institute of Technology, Stockholm, Sweden.

Mikael C Puustinen (MC)

Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Federico Miozzo (F)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
Neuroscience Institute-CNR (IN-CNR), Milan, Italy.

Patricia Fergelot (P)

Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France and INSERM U1211, University of Bordeaux, Bordeaux, France.

Élise Lebigot (É)

Service de Biochimie-pharmaco-toxicologie, Hôpital Bicêtre, Hopitaux Universitaires Paris-Sud, 94270 Le Kremlin Bicêtre, Paris-Sud, France.

Alain Verloes (A)

Université de Paris, INSERM, NeuroDiderot, Robert-Debré Hospital, F-75019, Paris, France.
Genetics Department, AP-HP, Robert-Debré University Hospital, Paris, France.

Pierre Gressens (P)

Université de Paris, INSERM, NeuroDiderot, Robert-Debré Hospital, F-75019, Paris, France.

Didier Lacombe (D)

Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France and INSERM U1211, University of Bordeaux, Bordeaux, France.

Jessica Gobbo (J)

INSERM, UMR1231, Laboratoire d'Excellence LipSTIC, Dijon, France.
University of Bourgogne Franche-Comté, Dijon, France.
Département d'Oncologie médicale, Centre Georges-François Leclerc, Dijon, France.

Carmen Garrido (C)

INSERM, UMR1231, Laboratoire d'Excellence LipSTIC, Dijon, France.
University of Bourgogne Franche-Comté, Dijon, France.
Département d'Oncologie médicale, Centre Georges-François Leclerc, Dijon, France.

Sandy D Westerheide (SD)

Department of Cell Biology, Microbiology, and Molecular Biology, College of Arts and Sciences, University of South Florida, Tampa, FL, USA.

Laurent David (L)

Université de Nantes, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000, Nantes, France.

Michel Petitjean (M)

Université de Paris, CNRS, Unité de Biologie Fonctionnelle et Adaptative, Paris, France.

Olivier Taboureau (O)

Université de Paris, CNRS, Unité de Biologie Fonctionnelle et Adaptative, Paris, France.

Fernando Rodrigues-Lima (F)

Université de Paris, CNRS, Unité de Biologie Fonctionnelle et Adaptative, Paris, France.

Sandrine Passemard (S)

Université de Paris, INSERM, NeuroDiderot, Robert-Debré Hospital, F-75019, Paris, France.

Délara Sabéran-Djoneidi (D)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.

Laurent Nguyen (L)

Laboratory of Molecular Regulation of Neurogenesis, GIGA-Stem Cells and GIGA-Neurosciences, Interdisciplinary Cluster for Applied Genoproteomics (GIGA-R), University of Liège, CHU Sart Tilman, Liège, Belgium.

Madeline Lancaster (M)

MRC Laboratory of Molecular Biology, Cambridge Biomedical, Campus, Cambridge, UK.

Lea Sistonen (L)

Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Valérie Mezger (V)

Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France. valerie.mezger@univ-paris-diderot.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH